 | • レポートコード：GIR-107A12087 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、124ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、胆管がん治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。胆管がん治療薬の種類別市場規模（5-フルオロウラシル（5-FU）、ゲムシタビン、シスプラチン、カペシタビン、オキサリプラチン、その他）、用途別市場規模（病院・クリニック、がん治療センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・胆管がん治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Celgene、Mylan、Eli Lilly、Johnson & Johnson、Accord Healthcare、Roche、Teva、AbbVie、Bristol-Myers Squibb、Pfizer、Intercept Pharmaceuticals、Novartis、Sanofi、Kyowa Hakko Kirin、Delcath Systems、Fresenius Kabi ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：5-フルオロウラシル（5-FU）、ゲムシタビン、シスプラチン、カペシタビン、オキサリプラチン、その他 ・用途別分析2016年-2026年：病院・クリニック、がん治療センター、その他 ・胆管がん治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・胆管がん治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・胆管がん治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・胆管がん治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・胆管がん治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Bile Duct Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Bile Duct Cancer Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Bile Duct Cancer Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Bile Duct Cancer Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
5-Fluorouracil (5-FU)
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Others
Market segment by Application, can be divided into
Hospitals & Clinic
Cancer Treatment Centers
Others
Market segment by players, this report covers
Celgene
Mylan
Eli Lilly
Johnson & Johnson
Accord Healthcare
Roche
Teva
AbbVie
Bristol-Myers Squibb
Pfizer
Intercept Pharmaceuticals
Novartis
Sanofi
Kyowa Hakko Kirin
Delcath Systems
Fresenius Kabi
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Bile Duct Cancer Drugs
1.2 Classification of Bile Duct Cancer Drugs by Type
1.2.1 Overview: Global Bile Duct Cancer Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Bile Duct Cancer Drugs Revenue Market Share by Type in 2020
1.2.3 5-Fluorouracil (5-FU)
1.2.4 Gemcitabine
1.2.5 Cisplatin
1.2.6 Capecitabine
1.2.7 Oxaliplatin
1.2.8 Others
1.3 Global Bile Duct Cancer Drugs Market by Application
1.3.1 Overview: Global Bile Duct Cancer Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals & Clinic
1.3.3 Cancer Treatment Centers
1.3.4 Others
1.4 Global Bile Duct Cancer Drugs Market Size & Forecast
1.5 Global Bile Duct Cancer Drugs Market Size and Forecast by Region
1.5.1 Global Bile Duct Cancer Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Bile Duct Cancer Drugs Market Size by Region, (2016-2021)
1.5.3 North America Bile Duct Cancer Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Bile Duct Cancer Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Bile Duct Cancer Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Bile Duct Cancer Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Bile Duct Cancer Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Bile Duct Cancer Drugs Market Drivers
1.6.2 Bile Duct Cancer Drugs Market Restraints
1.6.3 Bile Duct Cancer Drugs Trends Analysis
2 Company Profiles
2.1 Celgene
2.1.1 Celgene Details
2.1.2 Celgene Major Business
2.1.3 Celgene Bile Duct Cancer Drugs Product and Solutions
2.1.4 Celgene Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Celgene Recent Developments and Future Plans
2.2 Mylan
2.2.1 Mylan Details
2.2.2 Mylan Major Business
2.2.3 Mylan Bile Duct Cancer Drugs Product and Solutions
2.2.4 Mylan Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Mylan Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Bile Duct Cancer Drugs Product and Solutions
2.3.4 Eli Lilly Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business
2.4.3 Johnson & Johnson Bile Duct Cancer Drugs Product and Solutions
2.4.4 Johnson & Johnson Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Johnson & Johnson Recent Developments and Future Plans
2.5 Accord Healthcare
2.5.1 Accord Healthcare Details
2.5.2 Accord Healthcare Major Business
2.5.3 Accord Healthcare Bile Duct Cancer Drugs Product and Solutions
2.5.4 Accord Healthcare Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Accord Healthcare Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Bile Duct Cancer Drugs Product and Solutions
2.6.4 Roche Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Roche Recent Developments and Future Plans
2.7 Teva
2.7.1 Teva Details
2.7.2 Teva Major Business
2.7.3 Teva Bile Duct Cancer Drugs Product and Solutions
2.7.4 Teva Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Teva Recent Developments and Future Plans
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Bile Duct Cancer Drugs Product and Solutions
2.8.4 AbbVie Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 AbbVie Recent Developments and Future Plans
2.9 Bristol-Myers Squibb
2.9.1 Bristol-Myers Squibb Details
2.9.2 Bristol-Myers Squibb Major Business
2.9.3 Bristol-Myers Squibb Bile Duct Cancer Drugs Product and Solutions
2.9.4 Bristol-Myers Squibb Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Bile Duct Cancer Drugs Product and Solutions
2.10.4 Pfizer Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Pfizer Recent Developments and Future Plans
2.11 Intercept Pharmaceuticals
2.11.1 Intercept Pharmaceuticals Details
2.11.2 Intercept Pharmaceuticals Major Business
2.11.3 Intercept Pharmaceuticals Bile Duct Cancer Drugs Product and Solutions
2.11.4 Intercept Pharmaceuticals Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Intercept Pharmaceuticals Recent Developments and Future Plans
2.12 Novartis
2.12.1 Novartis Details
2.12.2 Novartis Major Business
2.12.3 Novartis Bile Duct Cancer Drugs Product and Solutions
2.12.4 Novartis Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Novartis Recent Developments and Future Plans
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Bile Duct Cancer Drugs Product and Solutions
2.13.4 Sanofi Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Sanofi Recent Developments and Future Plans
2.14 Kyowa Hakko Kirin
2.14.1 Kyowa Hakko Kirin Details
2.14.2 Kyowa Hakko Kirin Major Business
2.14.3 Kyowa Hakko Kirin Bile Duct Cancer Drugs Product and Solutions
2.14.4 Kyowa Hakko Kirin Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Kyowa Hakko Kirin Recent Developments and Future Plans
2.15 Delcath Systems
2.15.1 Delcath Systems Details
2.15.2 Delcath Systems Major Business
2.15.3 Delcath Systems Bile Duct Cancer Drugs Product and Solutions
2.15.4 Delcath Systems Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Delcath Systems Recent Developments and Future Plans
2.16 Fresenius Kabi
2.16.1 Fresenius Kabi Details
2.16.2 Fresenius Kabi Major Business
2.16.3 Fresenius Kabi Bile Duct Cancer Drugs Product and Solutions
2.16.4 Fresenius Kabi Bile Duct Cancer Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Fresenius Kabi Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Bile Duct Cancer Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Bile Duct Cancer Drugs Players Market Share
3.2.2 Top 10 Bile Duct Cancer Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Bile Duct Cancer Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Bile Duct Cancer Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Bile Duct Cancer Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Bile Duct Cancer Drugs Revenue Market Share by Application (2016-2021)
5.2 Bile Duct Cancer Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Bile Duct Cancer Drugs Revenue by Type (2016-2026)
6.2 North America Bile Duct Cancer Drugs Revenue by Application (2016-2026)
6.3 North America Bile Duct Cancer Drugs Market Size by Country
6.3.1 North America Bile Duct Cancer Drugs Revenue by Country (2016-2026)
6.3.2 United States Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Bile Duct Cancer Drugs Revenue by Type (2016-2026)
7.2 Europe Bile Duct Cancer Drugs Revenue by Application (2016-2026)
7.3 Europe Bile Duct Cancer Drugs Market Size by Country
7.3.1 Europe Bile Duct Cancer Drugs Revenue by Country (2016-2026)
7.3.2 Germany Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
7.3.3 France Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Bile Duct Cancer Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Bile Duct Cancer Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Bile Duct Cancer Drugs Market Size by Region
8.3.1 Asia-Pacific Bile Duct Cancer Drugs Revenue by Region (2016-2026)
8.3.2 China Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8.3.5 India Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Bile Duct Cancer Drugs Revenue by Type (2016-2026)
9.2 South America Bile Duct Cancer Drugs Revenue by Application (2016-2026)
9.3 South America Bile Duct Cancer Drugs Market Size by Country
9.3.1 South America Bile Duct Cancer Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Bile Duct Cancer Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Bile Duct Cancer Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Bile Duct Cancer Drugs Market Size by Country
10.3.1 Middle East & Africa Bile Duct Cancer Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Bile Duct Cancer Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Bile Duct Cancer Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Bile Duct Cancer Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Bile Duct Cancer Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Bile Duct Cancer Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Bile Duct Cancer Drugs Revenue Market Share by Region (2021-2026)
Table 6. Celgene Corporate Information, Head Office, and Major Competitors
Table 7. Celgene Major Business
Table 8. Celgene Bile Duct Cancer Drugs Product and Solutions
Table 9. Celgene Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Mylan Corporate Information, Head Office, and Major Competitors
Table 11. Mylan Major Business
Table 12. Mylan Bile Duct Cancer Drugs Product and Solutions
Table 13. Mylan Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly Major Business
Table 16. Eli Lilly Bile Duct Cancer Drugs Product and Solutions
Table 17. Eli Lilly Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 19. Johnson & Johnson Major Business
Table 20. Johnson & Johnson Bile Duct Cancer Drugs Product and Solutions
Table 21. Johnson & Johnson Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Accord Healthcare Corporate Information, Head Office, and Major Competitors
Table 23. Accord Healthcare Major Business
Table 24. Accord Healthcare Bile Duct Cancer Drugs Product and Solutions
Table 25. Accord Healthcare Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Roche Corporate Information, Head Office, and Major Competitors
Table 27. Roche Major Business
Table 28. Roche Bile Duct Cancer Drugs Product and Solutions
Table 29. Roche Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Teva Corporate Information, Head Office, and Major Competitors
Table 31. Teva Major Business
Table 32. Teva Bile Duct Cancer Drugs Product and Solutions
Table 33. Teva Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. AbbVie Corporate Information, Head Office, and Major Competitors
Table 35. AbbVie Major Business
Table 36. AbbVie Bile Duct Cancer Drugs Product and Solutions
Table 37. AbbVie Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 39. Bristol-Myers Squibb Major Business
Table 40. Bristol-Myers Squibb Bile Duct Cancer Drugs Product and Solutions
Table 41. Bristol-Myers Squibb Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Pfizer Corporate Information, Head Office, and Major Competitors
Table 43. Pfizer Major Business
Table 44. Pfizer Bile Duct Cancer Drugs Product and Solutions
Table 45. Pfizer Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Intercept Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Intercept Pharmaceuticals Major Business
Table 48. Intercept Pharmaceuticals Bile Duct Cancer Drugs Product and Solutions
Table 49. Intercept Pharmaceuticals Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Novartis Corporate Information, Head Office, and Major Competitors
Table 51. Novartis Major Business
Table 52. Novartis Bile Duct Cancer Drugs Product and Solutions
Table 53. Novartis Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Sanofi Corporate Information, Head Office, and Major Competitors
Table 55. Sanofi Major Business
Table 56. Sanofi Bile Duct Cancer Drugs Product and Solutions
Table 57. Sanofi Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Kyowa Hakko Kirin Corporate Information, Head Office, and Major Competitors
Table 59. Kyowa Hakko Kirin Major Business
Table 60. Kyowa Hakko Kirin Bile Duct Cancer Drugs Product and Solutions
Table 61. Kyowa Hakko Kirin Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Delcath Systems Corporate Information, Head Office, and Major Competitors
Table 63. Delcath Systems Major Business
Table 64. Delcath Systems Bile Duct Cancer Drugs Product and Solutions
Table 65. Delcath Systems Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Fresenius Kabi Corporate Information, Head Office, and Major Competitors
Table 67. Fresenius Kabi Major Business
Table 68. Fresenius Kabi Bile Duct Cancer Drugs Product and Solutions
Table 69. Fresenius Kabi Bile Duct Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Global Bile Duct Cancer Drugs Revenue (USD Million) by Players (2019-2021)
Table 71. Global Bile Duct Cancer Drugs Revenue Share by Players (2019-2021)
Table 72. Breakdown of Bile Duct Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 73. Bile Duct Cancer Drugs Players Head Office, Products and Services Provided
Table 74. Bile Duct Cancer Drugs Mergers & Acquisitions in the Past Five Years
Table 75. Bile Duct Cancer Drugs New Entrants and Expansion Plans
Table 76. Global Bile Duct Cancer Drugs Revenue (USD Million) by Type (2016-2021)
Table 77. Global Bile Duct Cancer Drugs Revenue Share by Type (2016-2021)
Table 78. Global Bile Duct Cancer Drugs Revenue Forecast by Type (2021-2026)
Table 79. Global Bile Duct Cancer Drugs Revenue by Application (2016-2021)
Table 80. Global Bile Duct Cancer Drugs Revenue Forecast by Application (2021-2026)
Table 81. North America Bile Duct Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 82. North America Bile Duct Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 83. North America Bile Duct Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 84. North America Bile Duct Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 85. North America Bile Duct Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 86. North America Bile Duct Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 87. Europe Bile Duct Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 88. Europe Bile Duct Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 89. Europe Bile Duct Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 90. Europe Bile Duct Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 91. Europe Bile Duct Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 92. Europe Bile Duct Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 93. Asia-Pacific Bile Duct Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 94. Asia-Pacific Bile Duct Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 95. Asia-Pacific Bile Duct Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 96. Asia-Pacific Bile Duct Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 97. Asia-Pacific Bile Duct Cancer Drugs Revenue by Region (2016-2021) & (USD Million)
Table 98. Asia-Pacific Bile Duct Cancer Drugs Revenue by Region (2021-2026) & (USD Million)
Table 99. South America Bile Duct Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 100. South America Bile Duct Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 101. South America Bile Duct Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 102. South America Bile Duct Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 103. South America Bile Duct Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 104. South America Bile Duct Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
Table 105. Middle East & Africa Bile Duct Cancer Drugs Revenue by Type (2016-2021) & (USD Million)
Table 106. Middle East & Africa Bile Duct Cancer Drugs Revenue by Type (2021-2026) & (USD Million)
Table 107. Middle East & Africa Bile Duct Cancer Drugs Revenue by Application (2016-2021) & (USD Million)
Table 108. Middle East & Africa Bile Duct Cancer Drugs Revenue by Application (2021-2026) & (USD Million)
Table 109. Middle East & Africa Bile Duct Cancer Drugs Revenue by Country (2016-2021) & (USD Million)
Table 110. Middle East & Africa Bile Duct Cancer Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Bile Duct Cancer Drugs Picture
Figure 2. Global Bile Duct Cancer Drugs Revenue Market Share by Type in 2020
Figure 3. 5-Fluorouracil (5-FU)
Figure 4. Gemcitabine
Figure 5. Cisplatin
Figure 6. Capecitabine
Figure 7. Oxaliplatin
Figure 8. Others
Figure 9. Bile Duct Cancer Drugs Revenue Market Share by Application in 2020
Figure 10. Hospitals & Clinic Picture
Figure 11. Cancer Treatment Centers Picture
Figure 12. Others Picture
Figure 13. Global Bile Duct Cancer Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Bile Duct Cancer Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Bile Duct Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 16. Global Bile Duct Cancer Drugs Revenue Market Share by Region in 2020
Figure 17. North America Bile Duct Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Bile Duct Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Bile Duct Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Bile Duct Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Bile Duct Cancer Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Bile Duct Cancer Drugs Market Drivers
Figure 23. Bile Duct Cancer Drugs Market Restraints
Figure 24. Bile Duct Cancer Drugs Market Trends
Figure 25. Celgene Recent Developments and Future Plans
Figure 26. Mylan Recent Developments and Future Plans
Figure 27. Eli Lilly Recent Developments and Future Plans
Figure 28. Johnson & Johnson Recent Developments and Future Plans
Figure 29. Accord Healthcare Recent Developments and Future Plans
Figure 30. Roche Recent Developments and Future Plans
Figure 31. Teva Recent Developments and Future Plans
Figure 32. AbbVie Recent Developments and Future Plans
Figure 33. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Intercept Pharmaceuticals Recent Developments and Future Plans
Figure 36. Novartis Recent Developments and Future Plans
Figure 37. Sanofi Recent Developments and Future Plans
Figure 38. Kyowa Hakko Kirin Recent Developments and Future Plans
Figure 39. Delcath Systems Recent Developments and Future Plans
Figure 40. Fresenius Kabi Recent Developments and Future Plans
Figure 41. Global Bile Duct Cancer Drugs Revenue Share by Players in 2020
Figure 42. Bile Duct Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 43. Global Top 3 Players Bile Duct Cancer Drugs Revenue Market Share in 2020
Figure 44. Global Top 10 Players Bile Duct Cancer Drugs Revenue Market Share in 2020
Figure 45. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 46. Global Bile Duct Cancer Drugs Revenue Share by Type in 2020
Figure 47. Global Bile Duct Cancer Drugs Market Share Forecast by Type (2021-2026)
Figure 48. Global Bile Duct Cancer Drugs Revenue Share by Application in 2020
Figure 49. Global Bile Duct Cancer Drugs Market Share Forecast by Application (2021-2026)
Figure 50. North America Bile Duct Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 51. North America Bile Duct Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 52. North America Bile Duct Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 53. United States Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Canada Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Mexico Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Europe Bile Duct Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 57. Europe Bile Duct Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 58. Europe Bile Duct Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 59. Germany Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. France Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. United Kingdom Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Russia Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Italy Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Asia-Pacific Bile Duct Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 65. Asia-Pacific Bile Duct Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 66. Asia-Pacific Bile Duct Cancer Drugs Revenue Market Share by Region (2016-2026)
Figure 67. China Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Japan Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South Korea Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. India Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Southeast Asia Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Australia Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. South America Bile Duct Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 74. South America Bile Duct Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 75. South America Bile Duct Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 76. Brazil Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Argentina Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Middle East and Africa Bile Duct Cancer Drugs Sales Market Share by Type (2016-2026)
Figure 79. Middle East and Africa Bile Duct Cancer Drugs Sales Market Share by Application (2016-2026)
Figure 80. Middle East and Africa Bile Duct Cancer Drugs Revenue Market Share by Country (2016-2026)
Figure 81. Turkey Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. Saudi Arabia Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. UAE Bile Duct Cancer Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. Methodology
Figure 85. Research Process and Data Source
世界の胆管がん治療薬市場予測（～2024年） Bile duct connects the liver to the gallbladder and carries bile, which is synthesized by the liver and stored in the gallbladder. The main function of bile is breakdown of fat during digestion. Bile duct cancer is commonly known as cholangiocarcinoma. The specific cause of bile duct cancer is unkno…- 食道がん治療薬の世界市場 2019年版：種類別（フルオロウラシル、シスプラチン、ドセタキセル、カルボプラチン、その他）、用途別（標的療法、化学療法） Scope of the Report: The global Esophageal Cancer Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, a…
- 世界のがんホルモン療法剤市場 2021：企業別、地域別、種類・用途別 The Cancer Hormone Therapy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade re…
- 世界の回腸ナトリウム/胆汁酸共輸送体市場 2021：企業別、地域別、種類・用途別 The Ileal Sodium/Bile Acid Cotransporter market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 世界の尿管がん治療薬市場 2021：企業別、地域別、種類・用途別 The Ureter Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…